{"id":176471,"date":"2020-03-23T00:00:00","date_gmt":"2020-03-22T23:00:00","guid":{"rendered":"https:\/\/www.bcfi.be\/covid-19-lopinavir-ritonavir-kaletra-les-resultats-dune-premiere-etude-randomisee-sont-decevants-cette-association-reste-reservee-aux-patients-covid-19-hospitalises-gravement-malades\/"},"modified":"2026-04-02T19:10:39","modified_gmt":"2026-04-02T17:10:39","slug":"covid-19-lopinavir-ritonavir-kaletra-les-resultats-dune-premiere-etude-randomisee-sont-decevants-cette-association-reste-reservee-aux-patients-covid-19-hospitalises-gravement-malades","status":"publish","type":"post","link":"https:\/\/h.cbip.be\/fr\/covid-19-lopinavir-ritonavir-kaletra-les-resultats-dune-premiere-etude-randomisee-sont-decevants-cette-association-reste-reservee-aux-patients-covid-19-hospitalises-gravement-malades\/","title":{"rendered":"COVID-19 : lopinavir + ritonavir (Kaletra\u00ae) : les r\u00e9sultats d’une premi\u00e8re \u00e9tude randomis\u00e9e sont d\u00e9cevants ; cette association reste r\u00e9serv\u00e9e aux patients COVID-19 hospitalis\u00e9s gravement malades"},"content":{"rendered":"

Le lopinavir, en association avec le ritonavir pour augmenter la biodisponibilit\u00e9, est utilis\u00e9 hors indication chez des patients COVID-19 hospitalis\u00e9s gravement malades. Le choix de cette association est bas\u00e9 sur des signes (principalement d'\u00e9tudes in vitro) d'activit\u00e9 antivirale contre les coronavirus SARS-CoV (responsable du SRAS), MERS-CoV (responsable du MERS) et le r\u00e9cent SARS-CoV2 (responsable du COVID- 19). Une premi\u00e8re \u00e9tude randomis\u00e9e de lopinavir + ritonavir, men\u00e9e \u00e0 Wuhan (Chine) chez des patients COVID-19 hospitalis\u00e9s gravement malades, vient de montrer qu\u2019une am\u00e9lioration clinique ne s'est pas produite plus rapidement chez les patients recevant du lopinavir + ritonavir en plus du traitement standard que chez les patients n\u2019ayant re\u00e7u qu'un traitement standard<\/strong> [voir aussi l\u2019information de Sciensano dans \u00ab\u00a0Informations plus d\u00e9taill\u00e9es<\/a>\u201d]. L\u2019\u00e9tude a \u00e9t\u00e9 publi\u00e9e le 18 mars dans le New England Journal of Medicine<\/em> (l\u2019\u00e9tude<\/a> et l\u2019\u00e9ditorial<\/a> peuvent \u00eatre consult\u00e9s gratuitement).
\u00a0
Comme pour l'hydroxychloroquine et la chloroquine (voir notre communiqu\u00e9 du 20\/03\/20<\/a>), l'association lopinavir + ritonavir (Kaletra<\/a>\u00ae) doit \u00eatre r\u00e9serv\u00e9e durant l\u2019\u00e9pid\u00e9mie COVID-19 pour le traitement des patients hospitalis\u00e9s, dans le cadre d'\u00e9tudes. Tout comme Plaquenil\u00ae et la mati\u00e8re premi\u00e8re chloroquine, Kaletra\u00ae a \u00e9t\u00e9 mis en quarantaine par les autorit\u00e9s sanitaires belges, et les pharmacies ne recevront ce m\u00e9dicament que pour les patients trait\u00e9s de mani\u00e8re chronique par Kaletra\u00ae (voir le site web d\u2019Ophaco<\/a> et le site web de l'AFMPS<\/a>).<\/p>\n

<\/a>Informations plus d\u00e9taill\u00e9es<\/h3>\n

La proc\u00e9dure pour les h\u00f4pitaux<\/strong> et les sp\u00e9cialistes \u201c<\/strong>Traitement des patients hospitalis\u00e9s\u201d<\/a> (version (anglaise) du <\/strong>19\/03\/2020<\/strong><\/a>)\u201d [Sciensano] mentionne : \u201cLopinavir\/ritonavir has been recently shown not to provide clinical benefit in hospitalized patients with COVID-19. <\/em>Importantly, there was also no impact on viral excretion. This is in line with in vitro experiments with SARS-CoV2 but also SARS-CoV1. In this trial however, a possible benefit (shorter stay in ICU) was suggested in patient who were treated early (before 12 days of symptoms). Lopinavir\/ritonavir can still be therefore considered a second choice for the moment, when hydroxychloroquine is contraindicated, but only if this treatment could be administered early in the course of the disease (within 10 days after symptoms onset). We consider this treatment as futile if administered later on.<\/em>\u201d
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"

Le lopinavir, en association avec le ritonavir pour augmenter la […]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,61],"tags":[48,20213,20224,20226],"class_list":["post-176471","post","type-post","status-publish","format-standard","hentry","category-actualites","category-2020-fr","tag-actualites-covid-19","tag-import_tags","tag-import_tags-nl","tag-covid-19-update"],"_links":{"self":[{"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/176471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/comments?post=176471"}],"version-history":[{"count":1,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/176471\/revisions"}],"predecessor-version":[{"id":179050,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/176471\/revisions\/179050"}],"wp:attachment":[{"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/media?parent=176471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/categories?post=176471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/tags?post=176471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}